Presymptomatic diagnosis of neurofibromatosis 2 using linked genetic markers, neuroimaging, and ocular examinations

被引:17
作者
Baser, ME
Mautner, VF
Ragge, NK
Nechiporuk, A
Riccardi, VM
Klein, J
Sainz, J
Pulst, SM
机构
[1] UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,DIV NEUROL,SCH MED,LOS ANGELES,CA 90048
[2] UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,NEUROGENET LAB,SCH MED,LOS ANGELES,CA 90048
[3] UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,DEPT PEDIAT,SCH MED,LOS ANGELES,CA 90048
[4] ALLGEMEINES KRANKENHAUS OCHSENZOLL,HAMBURG,GERMANY
[5] NEUROFIBROMATOSIS INST,LA CRESCENTA,CA
关键词
D O I
10.1212/WNL.47.5.1269
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Neurofibromatosis 2 (NF2) is an autosomal dominant disorder that causes nervous system tumors and ocular abnormalities such as early-onset lenticular opacities. We assessed the clinical spectrum of NF2 at the time of presymptomatic DNA diagnosis in at-risk first-degree relatives. We studied five multigeneration NF2 families with short tandem repeat markers near the NF2 gene (NF2); gadolinium-enhanced high-resolution magnetic resonance imaging (GE-MRI); and ocular, dermatologic, and neurologic examinations. Eleven of 31 asymptomatic at-risk first-degree relatives were predicted by segregation analysis to be NF2 mutation carriers. Nine of the 11 NF2 mutation carriers were clinically evaluated. Four mutation carriers, including a 7-year-old had vestibular schwannomas, early-onset cataracts, or both. However, five mutation carriers did not have clinical abnormalities, including a 38-year-old with normal cranial and spinal GE-MRIs and a normal ocular examination. These results indicate that clinical abnormalities can be present in young, but absent in middle-aged, presymptomatic NF2 mutation carriers. By identifying presymptomatic NF2 mutation carriers, DNA diagnosis of NF2 can improve genetic counseling and clinical management, and possibly reduce psychosocial difficulties in at-risk individuals.
引用
收藏
页码:1269 / 1277
页数:9
相关论文
共 58 条
[1]  
*AD HOC COMM GEN T, 1995, AM J HUM GENET, V56, P327
[2]  
*AM COLL MED GEN R, 1994, AM J HUM GENET, V57, P1233
[3]   BILATERAL CEREBELLOPONTINE ANGLE TUMORS IN NEUROFIBROMATOSIS TYPE-2 [J].
BALDWIN, D ;
KING, TT ;
CHEVRETTON, E ;
MORRISON, AW .
JOURNAL OF NEUROSURGERY, 1991, 74 (06) :910-915
[4]  
Baser ME, 1996, AM J MED GENET, V64, P563, DOI 10.1002/(SICI)1096-8628(19960906)64:4<563::AID-AJMG7>3.0.CO
[5]  
2-Q
[6]   CONSERVATIVE TREATMENT OF PATIENTS WITH ACOUSTIC TUMORS [J].
BEDERSON, JB ;
VONAMMON, K ;
WICHMANN, WW ;
YASARGIL, MG .
NEUROSURGERY, 1991, 28 (05) :646-651
[7]   FAMILY WITH NEUROFIBROMATOSIS TYPE-2 AND AUTOSOMAL-DOMINANT HEARING-LOSS - IDENTIFICATION OF CARRIERS OF THE MUTATED NF2 GENE [J].
BIJLSMA, EK ;
MEREL, P ;
FLEURY, P ;
VANASPEREN, CJ ;
WESTERVELD, A ;
DELATTRE, O ;
THOMAS, G ;
HULSEBOS, TJM .
HUMAN GENETICS, 1995, 96 (01) :1-5
[8]  
BILLINGS PR, 1992, AM J HUM GENET, V50, P476
[9]  
BOERKOEL CF, 1995, AM J HUM GENET, V56, P887
[10]   GERMLINE MUTATIONS IN THE NEUROFIBROMATOSIS TYPE-2 TUMOR-SUPPRESSOR GENE [J].
BOURN, D ;
CARTER, SA ;
MASON, S ;
EVANS, DGR ;
STRACHAN, T .
HUMAN MOLECULAR GENETICS, 1994, 3 (05) :813-816